4N1Z
Crystal Structure of Human Farnesyl Diphosphate Synthase in Complex with BPH-1222
4N1Z の概要
| エントリーDOI | 10.2210/pdb4n1z/pdb |
| 関連するPDBエントリー | 4GA3 |
| 分子名称 | Farnesyl pyrophosphate synthase, PHOSPHATE ION, MAGNESIUM ION, ... (5 entities in total) |
| 機能のキーワード | alpha fold, synthase, ionization, dephosphorylation, cytosol, transferase |
| 由来する生物種 | Homo sapiens (human) |
| 細胞内の位置 | Cytoplasm: P14324 |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 40676.85 |
| 構造登録者 | Liu, Y.L.,Xia, Y.,Zhang, Y.,Verma, I.,Oldfield, E. (登録日: 2013-10-04, 公開日: 2014-12-10, 最終更新日: 2023-09-20) |
| 主引用文献 | Xia, Y.,Liu, Y.L.,Xie, Y.,Zhu, W.,Guerra, F.,Shen, S.,Yeddula, N.,Fischer, W.,Low, W.,Zhou, X.,Zhang, Y.,Oldfield, E.,Verma, I.M. A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin. Sci Transl Med, 6:263ra161-263ra161, 2014 Cited by PubMed Abstract: Lung cancer is the most common human malignancy and leads to about one-third of all cancer-related deaths. Lung adenocarcinomas harboring KRAS mutations, in contrast to those with EGFR and EML4-ALK mutations, have not been successfully targeted. We describe a combination therapy for treating these malignancies with two agents: a lipophilic bisphosphonate and rapamycin. This drug combination is much more effective than either agent acting alone in the KRAS G12D-induced mouse lung model. Lipophilic bisphosphonates inhibit both farnesyl and geranylgeranyldiphosphate synthases, effectively blocking prenylation of KRAS and other small G proteins (heterotrimeric GTP-binding protein, heterotrimeric guanine nucleotide-binding proteins) critical for tumor growth and cell survival. Bisphosphonate treatment of cells initiated autophagy but was ultimately unsuccessful and led to p62 accumulation and concomitant nuclear factor κB (NF-κB) activation, resulting in dampened efficacy in vivo. However, we found that rapamycin, in addition to inhibiting the mammalian target of rapamycin (mTOR) pathway, facilitated autophagy and prevented p62 accumulation-induced NF-κB activation and tumor cell proliferation. Overall, these results suggest that using lipophilic bisphosphonates in combination with rapamycin may provide an effective strategy for targeting lung adenocarcinomas harboring KRAS mutations. PubMed: 25411474DOI: 10.1126/scitranslmed.3010382 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.35 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






